Determinants of C‐reactive protein in chronic hemodialysis patients: Relevance of dialysis catheter utilization

Biomarkers of inflammation, especially C‐reactive protein (CRP), have been consistently shown to predict poor outcomes in chronic hemodialysis (CHD) patients. However, the determinants of CRP and the value of its monitoring in CHD patients have not been well defined. We conducted a retrospective cohort study to evaluate possible determinants of the inflammatory response in CHD patients with a focus on dialysis catheter utilization. Monthly CRP were measured in 128 prevalent CHD patients (mean age 56.6 years [range 19–90], 68% African Americans, 39% diabetics [DM]) over a mean follow‐up of 12 months (range 2–26 months). There were a total of 2405 CRP measurements (median 5.7 mg/L; interquartile range [IQR] 2.4–16.6 mg/L). The presence of a dialysis catheter (p<0.002), cardiovascular disease (p=0.01), male gender (p=0.005), higher white blood cell count (p<0.0001), elevated phosphorus (p=0.03), and lower cholesterol (p=0.02) and albumin (p<0.0001) concentrations were independent predictors of elevated CRP in the multivariate analysis. Additionally, CRP levels were significantly associated with the presence of a catheter, when comparing the levels before and after catheter insertion (p=0.002) as well as before and after catheter removal (p=0.009). Our results indicate that the presence of a hemodialysis catheter is an independent determinant of an exaggerated inflammatory response in CHD patients representing a potentially modifiable risk factor.

[1]  F. Scolari,et al.  The Kind of Vascular Access Influences the Baseline Inflammatory Status and Epoetin Response in Chronic Hemodialysis Patients , 2006, Blood Purification.

[2]  Nancy R Cook,et al.  The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for Women , 2006, Annals of Internal Medicine.

[3]  F. Dekker,et al.  The effect of single and repeatedly high concentrations of C-reactive protein on cardiovascular and non-cardiovascular mortality in patients starting with dialysis. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  A. Ammirati,et al.  Coronary Artery Calcification, Systemic Inflammation Markers and Mineral Metabolism in a Peritoneal Dialysis Population , 2006, Nephron Clinical Practice.

[5]  F. Scolari,et al.  A High Calcium-Phosphate Product Is Associated with High C-Reactive Protein Concentrations in Hemodialysis Patients , 2005, Nephron Clinical Practice.

[6]  R. Marcén,et al.  Clinical Significance of C-Reactive Protein in Patients on Hemodialysis: A Longitudinal Study , 2005, Nephron Clinical Practice.

[7]  K. D. Workgroup K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  R. Manfro,et al.  The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: a prospective study. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  P. Bagos,et al.  Exploring Inflammation in Hemodialysis Patients: Persistent and Superimposed Inflammation , 2004, Kidney and Blood Pressure Research.

[10]  Mark B Pepys,et al.  C-reactive protein: a critical update. , 2003, The Journal of clinical investigation.

[11]  Sidney C. Smith,et al.  MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION , 2003 .

[12]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[13]  W. McClellan,et al.  Vascular access and increased risk of death among hemodialysis patients. , 2002, Kidney international.

[14]  H. Müller,et al.  The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients , 2000 .

[15]  G. Kaysen,et al.  C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  T. Ikizler,et al.  Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. , 1999, Kidney international.

[17]  P. Stenvinkel,et al.  Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. , 1999, Kidney international.

[18]  C. Wanner,et al.  Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. , 1999, Kidney international.

[19]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[20]  H. Müller,et al.  The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. The HEMO Study Group. , 2000, Kidney international.

[21]  Aileen B. Sedman,et al.  A longitudinal study , 1987 .